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Invasion of the host cell via CD147 spike protein has emerged 
as a novel mechanism of direct myocardial injury.(6) CD147, also 
called Basigin, is a transmembrane glycoprotein and is involved 
in viral infection, tumour development and invasion by the 
malarial parasite. It is expressed in haematopoietic, epithelial 
and endothelial cells and is upregulated in early erythroblasts, 
cardiac tissue, the placenta and thyroid.(7) Interaction of the 
spike protein and ACE2 promotes invasion of the virus into 
host cells. 
It is unclear whether myocarditis is a result of direct viral 
invasion of the heart or whether it is secondary to the pro-
inflammatory milieu.(8) 
Indirect effects
Systemic inflammatory response to the virus results in a 
cytokine-mediated storm culminating in multi-organ failure, 
including the heart.(9)
Myocardial injury in the context of SARS-CoV-2 frequently 
results from impaired myocardial oxygen demand and supply 
ratio.(10) Injury to the myocardium results from a combination 
of hypoxia, sepsis with increased myocardial demand, and 
anaemia. 
Myocardial infarction secondary to plaque rupture is attri-
buted to inflammatory response from the virus and possibly a 
pro-thrombotic state.(11)
Arrhythmias have been noted – especially in patients hospi-
talised in intensive care units with severe disease. These may be 
attributed to effects of drugs and electrolyte imbalances.(12,13)
INTRODUCTION
Coronaviruses belong to the subfamily Orthocoronavirinae. 
They are enveloped viruses that comprise a single stranded 
RNA genome and a nucleocapsid.(1) The SARS-CoV-2 out-
break was f irst recognised in Wuhan, China, in late 2019.(2) 
It has since been declared a pandemic. As of 26 April 2020, 
over 2.9 million confirmed cases of SARS-CoV-2 and 203 917 
deaths have been recorded worldwide.(3) 
Most patients present with a respiratory illness.(4) Patients with 
pre-existing cardiovascular disease, especially the elderly, are 
at high risk of complications and poor outcomes, if infected 
with SARS-CoV-2. Studies from China have shown that there 
is a high prevalence of cardiovascular disease, hypertension 
and diabetes amongst symptomatic COVID-19 patients.(4)
PATHOPHYSIOLOGY
It is postulated that COVID-19 affects the cardiovascular sys-
tem in a direct and indirect manner. 
Direct effects
Direct effects are mediated by the binding of the SARS-
CoV-2 to the angiotensin-converting enzyme (ACE2) recep-
tor expressed in the lungs and the heart, among other organs. 
Binding of SARS-CoV-2 to this receptor results in activation of 
the renin-angiotensin system, resulting in endothelial dysfunc-
tion in various organs including the heart.(5)
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COVID-19 or SARS-CoV-2, a novel coronavirus, has 
rapidly spread across the globe, resulting in millions of 
infections and thousands of deaths. In this short review 
we describe the pathophysiology, clinical and echo-
cardiographic manifestations of the virus, with specifi c 
reference to the cardiovascular system. We conclude 
with a case summary refl ective of the most common 
cardiovascular presentation in severely ill patients.
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Stress-induced cardiomyopathy, or takotsubo cardiomyopathy, 
likely attributed to the acute stress response at the population 
level and/or severe respiratory infection, has been described in 
a recent case report.(14)
COMMON ECHOCARDIOGRAPHIC 
CHARACTERISTICS OF COVID-19
From the current literature review the following echo-
cardiographic characteristics must be sought in patients afflicted 
with COVID-19: 
Left ventricular (LV) systolic dysfunction due to SARS-CoV-2 
results from wall motion abnormalities that can be either global 
or regional. This may be a result of myocarditis or coronary 
artery disease or stress-induced cardiomyopathy.(8,11) Regional 
wall motion abnormalities commonly tend to involve the 
infero-postero-lateral wall at the base of the heart in myocar-
ditis but may also involve other regions of the LV. Coronary 
artery disease (CAD) must be considered as an important 
differential in the context of COVID-19, as patients may pre-
sent with acute coronary syndrome. Therefore, the patient’s 
clinical context and accompanying symptoms must be taken 
into account.  Detection of wall motion abnormality in the 
typical distribution of a coronary artery favours the diagnosis 
of CAD.
Stress-induced cardiomyopathy typically is characterised by 
apical ballooning with hyperkinesia of the base.(15) Cases of 
reverse takotsubo cardiomyopathy have been described in the 
context of COVID-19.(14) Reverse takotsubo cardiomyopathy 
results in ballooning or hypokinesia of the base with apical 
hyperkinesia. Rarely, it may be complicated by LV apical throm-
bus and myocardial rupture.(15)
LV diastolic dysfunction may result from increased afterload on 
the left ventricle from activation of the renin angiotensin system 
by SARS-CoV-2-mediated activation of ACE2 receptors.(5) Also 
in patients with acute respiratory distress syndrome (ARDS), 
right ventricular (RV) enlargement impedes LV filling in diastole 
due to paradoxical septal motion.(16) 
ARDS results in pulmonary hypertension and causes pressure 
overload of the RV.(16) Furthermore, a pro-thrombotic state in 
COVID-19 predisposes to pulmonary embolism and throm-
botic microangiopathy, which can further contribute to RV 
enlargement and dysfunction.(17) However, RV involvement can 
also occur as part of myocarditis in the absence of respiratory 
involvement.(18) 
Pericardial effusion may occur as part of myopericarditis or 
decompensated heart failure, due to additional systemic inflam-
matory response from COVID-19 infection.(19) 
CLINICAL VIGNETTE
A middle-aged, obese, hypertensive female presented with 
shortness of breath and suspected myocardial infarction. On 
arrival, she was in severe respiratory distress with bilateral 
crackles. She had a clinical diagnosis of pneumonia and was 
not in heart failure. There were bilateral patchy infiltrates on 
chest radiograph and computed tomography of the chest 
(Figure 1). Her 12-lead electrocardiograph showed right 
bundle branch block, left anterior fascicular block and sinus 
tachycardia (Figure 2). An echocardiogram revealed left 
FIGURE 1: Chest X-ray (A) showing bilateral diffuse patchy infiltrates and computed tomography of the chest, (B) with 
typical ground glass opacification of the lungs consistent with SARS-CoV-2 pneumonia.
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FIGURE 2: Twelve lead electrocardiogram done on an ill patient at index presentation, showing right bundle branch 
block, left anterior fascicular block and sinus tachycardia.
FIGURE 3: RV enlargement secondary to COVID-19 pneumonia complicated by moderate tricuspid regurgitation and mild 
pulmonary hypertension. (A) Parasternal long-axis view depicting LV hypertrophy and RV enlargement. (B) Parasternal short-axis view 
showing pressure overload of the RV with flattening of the interventricular septum (arrow). (C) Right atrium and ventricle measurements 

















ventricular hypertrophy with preserved ejection fraction, no 
regional wall motion abnormality and right ventricular 
enlargement with pulmonary artery systolic pressure of about 
36mmHg (Figure 3). Her troponin-T assay was elevated, and 
her blood chemistry was suggestive of sepsis complicated by 
disseminated intravascular coagulation and acute renal failure. 
She was HIV negative. She tested positive for COVID-19. She 
received intensive supportive care and made a remarkable 
recovery. 
CONCLUSION
COVID-19 has a myriad of cardiovascular manifestations. 
Respiratory symptoms, with or without cardiac symptoms, tend 
to predominate – as in this case.  As the COVID-19 pandemic 
continues to unfold, it is incumbent upon all clinicians to 
maintain a high index of suspicion for the disease, especially in a 
patient with comorbid conditions. 
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